AdvaMed adds HHS health policy adviser
Executive Summary
Ann-Marie Lynch joins AdvaMed as exec VP-payment and healthcare delivery, bringing more than 15 years of health care policy experience to the post, the device trade group reports. Lynch served most recently as principal deputy assistant secretary in the HHS Office of the Assistant Secretary for Planning & Evaluation. She will join AdvaMed Oct. 24, succeeding exec VP Carol Kelly, who left the association in June to become director of CMS' new Office of Policy (1"The Pink Sheet" May 30, 2005, In Brief)....
You may also be interested in...
CMS Office of Policy
AdvaMed Exec VP Carol Kelly will join the Centers for Medicare & Medicaid Services to head a newly formed Office of Policy June 13. Kelly will lead a staff drawn from CMS' current Planning & Policy Analysis Group within the Office of Research, Development & Information. ORDI's Mary Ellen Stahlman will be assistant director of the office. Kelly joined AdvaMed in 1999; she previously worked at CMS (formerly known as HCFA) from 1982-1986...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Over The Counter 2 Apr 2024: Analyzing The Spin-Out Trend In Consumer Health, With HBW’s Malcolm Spicer And Tom Gallen
In this episode, HBW Insight’s Europe and US editors bring their expertise to bear on the current the trend towards standalone OTC companies in global consumer health. We look at four major players: Haleon, which separated from GSK almost two years ago; Kenvue, soon to celebrate its first anniversary as a new company; Sanofi Consumer Healthcare, which is poised to split from its pharma parent; and Bayer, which has decided to buck the trend, holding on to its consumer health division. We discuss some of the advantages of becoming a standalone company, for example in leaning into a wider concept of self-care.